Home Corindus Vascular Robotics, Inc.

Corindus Vascular Robotics, Inc.

    Corindus Vascular Robotics Announces Definitive Agreement to Be Acquired by Siemens Healthineers

    Mark J. Toland, President and Chief Executive Officer of Corindus. “We believe the transaction will deliver immediate, compelling and certain value to all Corindus stockholders, as well as substantial benefits to our customers.

    CorPath® GRX Systems Installed at HCA Healthcare Facilities

    The new systems are now installed in hospital locations in Florida and Texas, bringing the total number of HCA hospitals utilizing CorPath GRX to three.

    5/7/19: Chesapeake Regional Medical Center Installs CorPath GRX Vascular Robotic Systems in All Cath Labs

    Chesapeake Regional Medical Center has installed the CorPath GRX Vascular Robotic Systems in all catheterization labs.

    Corindus Announces FDA Submission for Neurovascular Intervention Indication for CorPath® GRX Vascular Robotic System

    2/14/19: An expansion of CorPath GRX Vascular Robotic System to treat neurovascular conditions would represent a major stepping stone towards our goal of revolutionizing stroke treatment,” said Mark Toland, President and Chief Executive Officer of Corindus.

    Corindus to Feature Recent Advancements in Robotic Technology at SCAI 2018 Scientific Sessions

    4/23/18: Optimizing care with CorPath GRX: Hot topics in robotic interventions.

    Corindus Receives FDA Clearance for First Automated Robotic Movement in technIQ™ Series for CorPath GRX Platform

    3/5/18: -Corindus Vascular Robotics, Inc. (NYSE American: CVRS), a leading developer of precision vascular robotics, announced today that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the first automated robotic movement designed for the CorPath GRX platform.

    Corindus Receives FDA Clearance for CorPath® GRX System in Peripheral Vascular Interventions

    2/20/18: Corindus Vascular Robotics, Inc. (NYSE American:CVRS), a leading developer of precision vascular robotics, announced today that it received 510(k) clearance from the U.S. Food and Drug Administration for use of its CorPath GRX System in peripheral vascular interventions. The CorPath System is the first and only FDA-cleared medical device to bring robotic precision to both percutaneous coronary intervention and peripheral vascular intervention procedures.

    Corindus Partners with Houston Methodist DeBakey Heart & Vascular Center to Launch Premier Robotic Training Site for Physicians

    12/1/17: Corindus Vascular Robotics, Inc. (NYSE American: CVRS), a leading developer of precision vascular robotics, announced today that Houston Methodist DeBakey Heart & Vascular Center, a leading cardiovascular center located in the Texas Medical Center, has launched the first vascular robotic program in the Houston area with the installation of two CorPath GRX Systems.

    Corindus to Feature CorPath® GRX System at the Transcatheter Cardiovascular Therapeutics 2017 Conference

    Corindus Vascular Robotics, Inc. (NYSE American:CVRS), a leading developer of precision vascular robotics, announced today that it will be participating in the Transcatheter Cardiovascular Therapeutics (TCT) 2017 Conference to be held October 29 – November 2 in Denver, CO. Robotic-assisted percutaneous coronary intervention (PCI) will be featured throughout the conference, including in the exhibit hall, presentations, and during a breakfast symposium.

    Corindus Announces Opening of First International Robotic Training Center

    Corindus Vascular Robotics, Inc. announced today the opening of the first international CorPath GRX Robotic Center in Tokyo, Japan. Earlier this year, Corindus partnered...

    Corindus Announces First Patient Enrolled in PRECISION GRX Registry

    Corindus Vascular Robotics, Inc. , a leading developer of precision vascular robotics, today announced first patient enrollment in the PRECISION GRX Registry, a post-market...

    RECISION Registry Data on Robotic-Assisted PCI Presented During Late Breaking Clinical Trial Session at SCAI 2017

    Corindus Vascular Robotics, Inc. announced today the latest post-market findings from the PRECISION Registry at the 2017 Society for Cardiovascular Angiography and Interventions...

    Corindus to Feature CorPath® GRX System at the Society for Cardiovascular Angiography and Interventions (SCAI) 2017 Scientific Sessions

    Corindus Vascular Robotics, Inc. (NYSE MKT: CVRS) announced today that it will be participating in the SCAI 2017 Scientific Sessions to be held May...

    Corindus Announces 100th Robotic-Assisted PCI Procedure Performed Using 2nd Generation CorPath® GRX System

    Corindus Vascular Robotics, Inc. (NYSE MKT: CVRS) announced today the milestone of the 100th robotic-assisted percutaneous coronary intervention (PCI) case performed using the Company’s...

    Corindus Announces Live Broadcast of Robotic-assisted PCI using CorPath® GRX to TCT Asia-Pacific Summit in South Korea

      Tal Wenderow, Corindus Co-Founder and Executive Vice President International & Business Development, notes, "The Asia-Pacific region represents a variety of markets that are strategically...

    Corindus Announces First Robotic-Assisted PCI Procedures Performed in Asia Using CorPath® GRX System

      Corindus Announces First Robotic-Assisted PCI Procedures Performed in Asia Using CorPath® GRX System Corindus Vascular Robotics, Inc. (NYSE MKT: CVRS), a leading developer of precision...

    RECENT COMMENTS